Acamprosate
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ACAMPROSATE |
|---|---|
| Type | Drug |
| Aliases | Acamprosate calciumCampralАкампросат |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Glutamate (NMDA) and GABA modulator |
|---|---|
| Mechanism | Synthetic taurine analog with mixed action on NMDA glutamate receptors (modulator) and GABAergic neurotransmission. Restores glutamatergic excitatory / GABAergic inhibitory balance disrupted by chronic alcohol use. Used to maintain abstinence in alcohol use disorder (AUD) after successful detoxification. First-line FDA-approved AUD pharmacotherapy alongside naltrexone and disulfiram. No effect on intoxication or withdrawal — purely abstinence maintenance. |
| Typical dosing | PO: 666 mg (two 333 mg tablets) TID with meals (1998 mg total daily dose). Lower body weight (<60 kg) or older patients: consider 333 mg TID. Renal: CrCl 30-50 mL/min → 333 mg TID; CrCl <30 → contraindicated. Initiate AFTER alcohol detoxification (typically within 5 days of last drink) and continue ≥6-12 months even if relapses occur. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Notes
STUB — v0.2 prevention-workstream authoring; pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. First-line AUD pharmacotherapy for maintenance of abstinence. Particularly suited to patients with hepatic impairment (renal excretion only). TID dosing limits adherence — once-daily naltrexone often preferred unless renal-safety considerations dictate otherwise. Alcohol cessation is a cancer- prevention intervention (HCC, CRC, esophageal SCC, breast). Source cited is closest in-KB until NIAAA/APA AUD sources land.
Used By
No reverse references found in the YAML corpus.